Dr. Ma has over 30 years of insight and first-hand experience in R&D, cancer biology and transgenic research, target validation and preclinical studies.

He served as Director of R&D at FZata, Inc., where he led the team responsible for developing therapeutic nanobodies and novel delivery means to various targets by creating novel phage, yeast and mammalian cell libraries. He was also a senior scientist at CSPC Dophen where he led non-GLP studies of antibody-drug conjugates (ADC) to provide data for GLP studies and IND applications as an expert on explorations of MTD, FIH dose and toxicokinetic studies. Previously, he was a faculty member at the University of Maryland and a Senior Scientist at Lexicon Pharmaceuticals, Inc. with research interests in oncology drug discovery.

Dr. Ma received his Ph.D. degree in Biotechnology from the University of Milan, Italy and completed postdoctoral training at Baylor College of Medicine. Dr. Ma owns one patent and has over 30 publications.